Immortalized Rat Hepatocytes-SV40

Cat.No.: CSC-I9161L

Species: Rattus norvegicus

Source: Liver

Morphology: Polyhedral

Culture Properties: Adherent

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-I9161L
Description
Species
Rattus norvegicus
Source
Liver
Culture Properties
Adherent
Morphology
Polyhedral
Immortalization Method
Serial passaging and transduction with recombinant lentiviruses carrying SV40 Large T antigen
Application
For Research Use Only
Storage
Directly and immediately transfer cells from dry ice to liquid nitrogen upon receiving and keep the cells in liquid nitrogen until cell culture needed for experiments.

Note: Never can cells be kept at -20 °C.
Shipping
Dry Ice.
Recommended Products
CSC-7662W Cryopreserved Plateable RAT Hepatocytes, min of 4 million cells/vial
CIK-HT003 HT® Lenti-SV40T Immortalization Kit
Quality Control
Real Time PCR was used to quantify SV40 gene expression in immortalized cell line.
BioSafety Level
II
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

Immortalized rat hepatocyte cell lines generated via SV40 large T antigen are well-characterized in vitro models for studies in liver biology, drug metabolism, and toxicology.

The primary advantage of Immortalized Rat Hepatocytes-SV40 lies in their unlimited proliferative capacity combined with maintained hepatic differentiation functions. Unlike primary rat hepatocytes which rapidly lose liver‑specific characteristics upon culture, these cells retain measurable activities of phase I (cytochrome P450) and phase II drug‑metabolizing enzymes, with demonstrated inducibility by classic agents including phenobarbital (170% increase for CYPIIB), methylcholanthrene (500% increase for CYPIA), and dexamethasone.

Additional advantages include experimental reproducibility, high scalability, and absence of donor‑to‑donor variability that plagues primary hepatocyte preparations. The expression of SV40 large T antigen in these cells can be confirmed by qPCR, and rigorous quality control ensures they are free from mycoplasma, bacteria, and viral contaminants. Taken together, Immortalized Rat Hepatocytes-SV40 provides a reproducible, ethically uncomplicated, and functionally relevant platform for liver disease modeling, toxicogenomics, high‑throughput drug screening, and bioartificial liver support system development.

Evaluation of Immortalized Hepatocyte Encapsulated Click-Microbeads with RGD Peptide for Treatment of Liver Failure in Male Rats

Cell encapsulation in biocompatible microbeads offers a promising strategy for cell-based therapy in acute liver failure (ALF). This study evaluates the use of immortalized hepatocyte cells (imHCs) encapsulated in click-arginyl glycyl aspartic acid (click-RGD)-modified alginate microbeads, focusing on their biocompatibility and therapeutic potential. In vitro assessments showed that click-RGD microbeads significantly enhanced cell viability on day 4, spatial distribution, and hepatocyte function, evidenced by increased albumin on day 14 and alpha-fetoprotein (AFP) secretion compared to unmodified alginate microbeads. For in vivo testing, ALF was induced in Sprague-Dawley male rats using D-galactosamine (D-gal), followed by intraperitoneal administration of imHCs-loaded click-RGD microbeads in the treated group and CMRL medium injection in the control group. Treated rats exhibited faster reductions in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, higher albumin production, and improved liver histology, characterized by reduced necrosis and the absence of inflammation, on day 14 after treatment. No adverse host responses were observed, confirming the biocompatibility of the microbeads.

These findings support the potential of click-RGD microbeads as a therapeutic platform for ALF, warranting further studies on long-term implantation, immune response, and co-encapsulation strategies.

Albumin and AFP release from imHCs encapsulated in alginate and click-RGD microbeads.

Fig. 1. Cumulative release of hepatic markers from imHCs encapsulated in alginate and click-RGD microbeads (Win, Su Yee, et al., 2025).

Evaluation of hepatic biomarkers after injection with CMRL medium and imHCs encapsulated click-RGD microbeads.

Fig. 2. Serum biochemical analysis of liver function following CMRL medium or imHCs-click microbeads injection in D-gal-induced rats (Win, Su Yee, et al., 2025).

Ask a Question

Write your own review

For research use only. Not for any other purpose.

Hot Products